

Prepare your patients to interact with a Specialty Pharmacy

Common questions from patients about specialty pharmacies

Q What should I expect when getting TYMLOS from a specialty pharmacy?

A You should expect to speak directly with the specialty pharmacy **before your prescription can be dispensed**. These calls will likely come from a **toll-free number** and failure to pick up these calls can lead to not receiving your prescription.

Q How often should I expect to talk to a specialty pharmacy?

A	You should expect 3 calls:	Topics covered during each call:
	Welcome call Introduces you to the specialty pharmacy and the services it provides	<ul style="list-style-type: none"> • Type of support offered • Information you need for future calls • Information on who to contact if questions arise
	Delivery call Notifies you that your prescription has been filled, and determines shipment options and out-of-pocket costs	<ul style="list-style-type: none"> • Delivery requirements (e.g., if you need to be present) • Information on who to contact if you have problems or questions around taking TYMLOS • Availability of a savings card
	Refill call Reminds you that the specialty pharmacy is preparing a refill and shipment	<ul style="list-style-type: none"> • Monthly adherence and setting up automatic refills • Need for supplemental supplies (e.g., needles), counseling, or support

Q Will the specialty pharmacy assist me with finding financial support and/or savings?

A **Yes**, most specialty pharmacies will attempt to find financial support to offset a patient's out-of-pocket costs. If a patient is eligible for the TYMLOS Savings Card, make sure your patients tell their pharmacist to have it applied for every prescription fill.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.

IMPORTANT SAFETY INFORMATION

Contraindications: TYMLOS is contraindicated in patients with a history of systemic hypersensitivity to abaloparatide or to any component of the product formulation. Reactions have included anaphylaxis, dyspnea, and urticaria.

Risk of Osteosarcoma: It is unknown whether TYMLOS will cause osteosarcoma in humans. Osteosarcoma has been reported in patients treated with a PTH-analog in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of TYMLOS use. Avoid use of TYMLOS for patients at an increased baseline risk for osteosarcoma including patients with open epiphysis (pediatric and young adult patients); metabolic bone diseases other than osteoporosis, including Paget's disease of the bone; bone metastases or a history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; or hereditary disorders predisposing to osteosarcoma.

Please see Important Safety Information throughout. Please see full Prescribing Information at www.TYMLOSPI.com.

Remind your patients that **Specialty Pharmacies** offer convenient services such as:



Prescription refill reminders

Patients can set up helpful reminders to help ensure they receive TYMLOS regularly and stay on track with their treatment regimen.




At-home delivery

Patients can receive TYMLOS at home or at a location of their choosing, including their local retail pharmacy.



Dedicated support staff

In addition to receiving guidance from you and your office staff, your patients can speak with a knowledgeable and dedicated nurse or support staff member about their treatment.



Clinical counseling and support

Specialty pharmacies can help educate patients about dosing and administration of TYMLOS and may be able to provide at-home tutorials and visits to ensure patients are administering their medications correctly.

IMPORTANT SAFETY INFORMATION (cont'd)

Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia, or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Pregnancy and Lactation: TYMLOS is not indicated for use in females of reproductive potential.

Adverse Reactions: The most common adverse reactions (incidence $\geq 2\%$) reported with TYMLOS are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, and vertigo.

Please see Important Safety Information throughout. Please see full Prescribing Information at www.TYMLOSPI.com.